Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling

REFERENCES

• Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond). 2015;128(2):81-93; https://doi.org/10.1042/CS20140278
   PubMed Web of Science ®Google Scholar
• Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol. 2014; 307(1):C25-38; https://doi.org/10.1152/ajpcell.00084.2014
   PubMed Web of Science ®Google Scholar
• Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995;1173-91.
   Web of Science ®Google Scholar
• Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol. 1997; 173(2):206-10; https://doi.org/10.1002/(SICI)1097-4652(199711)173:2%3c206::AID-JCP22%3e3.0.CO;2-C
   PubMed Web of Science ®Google Scholar
• McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol. 2006; 241(3):564-89; https://doi.org/10.1016/j.jtbi.2005.12.022
   PubMed Web of Science ®Google Scholar
• Spill F, Guerrero P, Alarcon T, Maini PK, Byrne HM. Mesoscopic and continuum modelling of angiogenesis. J Math Biol. 2015; 70(3):485-532; https://doi.org/10.1007/s00285-014-0771-1
   PubMed Web of Science ®Google Scholar
• Khurana R, Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med. 2003; 13(3):116-22; https://doi.org/10.1016/S1050-1738(02)00259-1
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904; https://doi.org/10.1158/1078-0432.CCR-04-0378
   PubMed Web of Science ®Google Scholar
• Bagri A, Kouros-Mehr H, Leong KG, Plowman GD. Use of anti-VEGF adjuvant therapy in cancer: Challenges and rationale. Trends Mol Med. 2010; 16(3):122-32; https://doi.org/10.1016/j.molmed.2010.01.004
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468(7325):824-8; https://doi.org/10.1038/nature09557
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005; 258(2):94-114; https://doi.org/10.1111/j.1365-2796.2005.01528.x
   PubMed Web of Science ®Google Scholar
• Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F. Nicotinic acid: A review of its clinical use in the treatment of lipid disorders. Pharmacotherapy. 1988; 8(5):287-94; https://doi.org/10.1002/j.1875-9114.1988.tb04085.x
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Zhang P, Niu H, Shi Y. Nicotinic acid modulates intracellular calcium concentration and disassembles the cytoskeleton. Mol Med Rep. 2014; 10(6):2805-10; https://doi.org/10.3892/mmr.2014.2576
   PubMed Web of Science ®Google Scholar
• Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009; 24(6):677-85; https://doi.org/10.1007/s00384-009-0655-9
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008; 26(21):3523-9; https://doi.org/10.1200/JCO.2007.15.4138
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: A pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013; 12(3):145-51; https://doi.org/10.1016/j.clcc.2013.04.006
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, et al. Study protocol of the TRICOLORE trial: A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer. 2015; 15:626; https://doi.org/10.1186/s12885-015-1630-1
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-85; https://doi.org/10.1016/S1470-2045(13)70154-2
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013; 14(1):29-37; https://doi.org/10.1016/S1470-2045(12)70477-1
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martinez de Prado P, Gallen M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study. Oncologist. 2012; 17(1):15-25; https://doi.org/10.1634/theoncologist.2011-0249
   PubMed Web of Science ®Google Scholar
• Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980):1843-52; https://doi.org/10.1016/S0140-6736(14)62004-3
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499-506; https://doi.org/10.1200/JCO.2012.42.8201
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863):303-12; https://doi.org/10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4; https://doi.org/10.1038/362841a0
   PubMed Web of Science ®Google Scholar
• Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res. 2005; 96(1):15-26; https://doi.org/10.1161/01.RES.0000153188.68898.ac
   PubMed Web of Science ®Google Scholar
• Saxena S, Jha S. Role of NOD- like receptors in glioma angiogenesis: insights into future therapeutic interventions. Cytokine Growth Factor Rev. 2017; 34:15-26; https://doi.org/10.1016/j.cytogfr.2017.02.001
   PubMed Web of Science ®Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8):610-22; https://doi.org/10.1038/nrn2175
   PubMed Web of Science ®Google Scholar
• Multhoff G, Radons J, Vaupel P. Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistance. Cancers (Basel). 2014; 6(2):813-28; https://doi.org/10.3390/cancers6020813
   PubMed Web of Science ®Google Scholar
• Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci. 2006; 27(7):384-90; https://doi.org/10.1016/j.tips.2006.05.008
   PubMed Web of Science ®Google Scholar